$50m-plus deal gives Daiichi Sankyo option to Amplimmune's T-cell inhibitor
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo is aiming to strengthen its pipeline for autoimmune disorders through an option deal with the private US firm Amplimmune for a novel but still preclinical stage immunomodulating molecule, AMP-110.